Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Παρασκευή 15 Δεκεμβρίου 2017

Progestin-primed ovarian stimulation with or without clomiphene citrate supplementation in normal ovulatory women undergoing IVF/ICSI: a prospective randomized controlled trial

Abstract

Objective

To compare the endocrinological profiles, cycle characteristics and pregnancy outcomes of progestin-primed ovarian stimulation (PPOS) with or without clomiphene citrate (CC) supplementation in normal ovulatory women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI).

Design

Prospective randomized controlled study.

Patient(s)

A total of 320 infertile women undergoing IVF/ICSI. Medroxyprogesterone acetate (MPA) and human menopausal gonadotropin (hMG) were simultaneously administered on menstrual cycle day 3. The women were randomized into two equal groups with or without CC supplementation.

Measures

The primary outcome measure was the percentage of women with profound pituitary suppression (luteinizing hormone (LH) < 1.0 IU/L on the trigger day). The secondary outcomes were endocrinological profiles, cycle characteristics and pregnancy outcomes.

Results

The percentage of women with profound pituitary suppression was significantly lower in the study group (hMG + MPA + CC) than in the control group (hMG + MPA) (1.9% vs. 33.1%, P < 0.001). The mean LH level during controlled ovarian stimulation (COS) was higher in the study group than in the control group (P < 0.001), but none of the patients in either group exhibited a premature LH surge. The doses of Gn in the study group were significantly lower than those in the control group (1334.06 ± 212.53 IU vs. 1488.28 ± 325.08 IU, P < 0.001). The number of oocytes retrieved was similar between the two groups (10.03 ± 5.97 vs. 10.34 ± 7.52, P > 0.05). No significant differences were observed in either the number of viable embryos or the pregnancy outcomes between the two groups.

Conclusion(s)

CC is an effective adjuvant to alleviate pituitary suppression in the PPOS protocol; however, it has no impact on clinical outcomes.

This article is protected by copyright. All rights reserved.



http://ift.tt/2AV65Jz

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου